I'll be keeping a close eye on this ASX fintech. The post Could this be a millionaire-maker ASX growth stock at 67 cents?

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said.